Compare ARTW & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARTW | PDSB |
|---|---|---|
| Founded | 1956 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 11.4M |
| IPO Year | 1996 | 2015 |
| Metric | ARTW | PDSB |
|---|---|---|
| Price | $3.19 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 1.6M | ★ 2.9M |
| Earning Date | 04-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.33 | 28.16 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $22,975,408.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $83.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.05 | $0.20 |
| 52 Week High | $4.17 | $1.55 |
| Indicator | ARTW | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 63.48 | 69.86 |
| Support Level | $2.54 | $0.51 |
| Resistance Level | $4.17 | $0.77 |
| Average True Range (ATR) | 0.17 | 0.03 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 87.65 | 98.09 |
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.